{"cluster": 57, "subcluster": 13, "abstract_summ": "CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting.TRIAL DESIGN: Double-blind, multi-centre, 2-arm (3:3:2 ratio) randomised placebo-controlled trial PARTICIPANTS: National Health Service (NHS) workers who have direct patient contact delivering care to patients with COVID-19.The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients.Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily.", "title_summ": "Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trialSafety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series studyHydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysisHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trialHydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trialHydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS): Protocol for a Pragmatic, Open Label, Active Comparator Trial.", "title_abstract_phrases": "CONCLUSION: Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting.TRIAL DESIGN: Double-blind, multi-centre, 2-arm (3:3:2 ratio) randomised placebo-controlled trial PARTICIPANTS: National Health Service (NHS) workers who have direct patient contact delivering care to patients with COVID-19.The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients.Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily."}